Fierce Pharma

FDA hands Pfizer, Arvinas’ Veppanu early approval for breast cancer subtype

Arvinas and Pfizer are the first to take a PROteolysis TArgeting Chimera (PROTAC) therapy across the FDA finish line, opening ...

Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer

VEPPANU™ is the first-and-only FDA-approved PROTAC, a type of heterobifunctional protein degrader –– Approval received in advance of ...
Morningstar

Pfizer and French partner to seek approval for Lyme disease vaccine after late-stage trial

Valneva shares slump after the companies said the study's primary endpoint didn't meet statistical significance Pfizer and Valneva plan to seek regulatory approval for a Lyme disease vaccine.
BioPharma Dive

Arvinas’ ‘Protac’ breast cancer drug cleared by FDA

Known as Veppanu, the drug is the first of its kind to get to market. But Arvinas and partner Pfizer are still searching for ...

When promising cures collapse before they reach patients

Hospitals filled to capacity. Case counts climbing by the hour. Quarantine became routine. It was the beginning of the ...